Novartis 2022 Financial Results
Novartis announced the company’s fourth quarter and 2022 full year financial results.
Novartis in Society Integrated Report 2022
The Novartis in Society Integrated Report covers our business, strategy and performance. It highlights progress against our ESG targets and describes how we create value for diverse stakeholders.
Annual Report 2022
This report provides a comprehensive overview of Novartis, including our company structure, corporate governance and compensation practices and contains our operating and financial results, accompanied by audited annual financial statements.
Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®
Novartis continues to grow with further core margin expansion and achieves important innovation milestones
World Economic Forum 2023
Novartis leaders went at the WEF Annual Meeting in Davos. Switzerland
Novartis condemns the war in Ukraine and has been providing humanitarian support, financial donations as well as considerable volumes of medicines to those people impacted by the war.
Novartis resumes business in Ukraine
After studying current safety protocols in the country, and on advice which we will regularly review, we have begun to resume business operations remotely to help the war-torn country restore some basic critical business processes.
Novartis provides more than USD 25 million in medical aid to patients in Ukraine and bordering countries
Novartis condemns the war in Ukraine. The continued acts of unprovoked violence are harming innocent people, and this defies our mission to improve human health globally.
Novartis has announced an intention to separate the Sandoz business to create a standalone company by way of a 100% spin-off.